Biohaven plunges as investors pit migraine data against Allergan's drug
(Reuters) - Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan's rival treatment.
from Reuters: Health News https://reut.rs/2IT2HPq
http://bit.ly/2zwRqiM